Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO
Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP appointed as CEO to drive growth ambitions Mosaic Therapeuti